# Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection

> **NCT00147381** · PHASE3 · COMPLETED · sponsor: **Dr. Claudia Bösmüller** · enrollment: 197 (actual)

## Conditions studied

- Kidney Transplantation

## Interventions

- **DRUG:** Alemtuzumab
- **DRUG:** Tacrolimus
- **DRUG:** Alemtuzumab

## Key facts

- **NCT ID:** NCT00147381
- **Lead sponsor:** Dr. Claudia Bösmüller
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2008-08
- **Final completion:** 2011-07
- **Target enrollment:** 197 (ACTUAL)
- **Last updated:** 2012-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00147381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00147381, "Effectiveness and Safety of Campath in Combination With Tacrolimus Monotherapy to Prevent Kidney Graft Rejection". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00147381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*